Navigation Links
Genomic Health Announces Expansion of Oncotype DX(R) Breast Cancer Test to Include Quantitative Estrogen Receptor (ER) and Progesterone Receptor (PR) Scores
Date:6/2/2008

Study Published in the Journal of Clinical Oncology Proves Accurate Measurement of ER and PR Status Using Quantitative Reverse-Transcriptase

Polymerase Chain Reaction (RT-PCR)

REDWOOD CITY, Calif., June 2 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the Journal of Clinical Oncology (JCO) published results of a study confirming RT-PCR by Oncotype DX can deliver quantitative gene expression levels for assessing estrogen receptor (ER) and progesterone receptor (PR) status, which are critical factors in determining the use and benefit of hormonal therapy for the treatment of breast cancer. Based on these results, Genomic Health is now providing quantitative ER and PR scores to physicians and patients in addition to the Recurrence Score(TM) result provided in the Oncotype DX(R) report.

Unlike traditional methodologies that provide either a positive or negative result, or a semi-quantitative result, RT-PCR by Oncotype DX generates a specific score across a continuous range of expression which allows physicians to factor the quantitative level of ER and PR gene expression into their treatment planning.

"Every breast tumor expresses the estrogen receptor gene at a specific level and, similar to other diagnostic measures, the ability to more accurately pinpoint that level increases the confidence in a diagnosis and treatment plan," said Sandra Swain, M.D., Medical Director, Washington Cancer Institute, Washington Hospital Center. "Having quantitative ER and PR scores provides added certainty in confirming expression levels of these important genes in predicting how likely a patient is to benefit from hormonal therapy."

This study published in JCO was originally presented at the American Society of Clinical Oncology Breast Cancer Symposium in September 2007. It measured ER and PR gene expression in 776 breast cancer patients by both local laboratory and central immunohistochemistry (IHC), and quantitative RT-PCR, as performed by the Oncotype DX assay. Results showed a high degree of agreement between the two methods. In an accompanying editorial, Dr. Craig Allred comments, "RT-PCR is at least equivalent to IHC in its ability to identify receptor-positive cases (considering ER and PR combined), marginally superior in predicting outcome in ER-positive patients, and superior in technical precision."

"We believe the methodology of the future is the quantitative measure of the biology of each individual tumor," said Steven Shak, M.D., chief medical officer of Genomic Health. "Providing physicians with quantitative ER and PR scores enhances the value of Oncotype DX by providing more patient-specific information to help individualize treatment decisions for breast cancer patients. We are continuing to conduct additional studies, including studying the use of RT-PCR by Oncotype DX to quantify HER-2 gene expression, another cancer-related gene that plays an important role in the determination of optimal treatment for breast cancer patients."

About Oncotype DX(R)

Oncotype DX is the first and only multi-gene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. Oncotype DX has been extensively evaluated in multiple independent studies involving more than 3,600 breast cancer patients, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. To date, 7,500 physicians have ordered more than 55,000 tests, and health plans covering over 80 percent of U.S. insured lives provide reimbursement for Oncotype DX through contracts, agreements and policy decisions. Both the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network recommend the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For more information about Oncotype DX, please visit http://www.oncotypedx.com.

About Genomic Health

Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test, Oncotype DX(R), which has been shown to predict the likelihood chemotherapy benefit as well as recurrence in early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's belief that the quantitative measurement of individual tumor biology is the methodology of the future and the belief that providing quantitative ER and PR scores enhances the value of Oncotype DX. These risks and uncertainties include, but are not limited to: the results of additional clinical studies; the risk that we may not obtain sufficient levels of reimbursement for any future tests we may develop; our ability to develop and commercialize new products; the risks and uncertainties associated with the regulation of our tests by FDA; our ability to obtain capital when needed; our history of operating losses and the other risks set forth in our filings with the Securities and Exchange Commission, including the risks set forth in our Quarterly Report on Form 10-Q for the three-month period ended March 31, 2008. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: Genomic Health, the Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.


'/>"/>
SOURCE Genomic Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ipsogen Launches MapQuant Dx(TM) Genomic Grade Test to Identify Breast Cancer Patients who Benefit From Chemotherapy
2. New insights into cellular reprogramming revealed by genomic analysis
3. /C O R R E C T I O N -- Rosetta Genomics Ltd/
4. Rosetta Genomics Reports First Quarter 2008 Financial Results
5. Rosetta Genomics Announces Conference Call and Webcast of First Quarter Financial Results
6. Albert Einstein College of Medicine Receives $25-Million Gift to Support Stem Cell and Epigenomic Research and Clinical Skills Training
7. Genomic Health Announces First Quarter 2008 Financial Results and Business Progress
8. ExonHit Launches Rat Genome SpliceArray(TM) Products to Expand High Resolution Gene Expression Profiling for use in Disease Modeling and Toxicogenomics
9. NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7, 2008
10. Genomic Health to Announce First Quarter 2008 Financial Results and Host Conference Call on Tuesday, May 6, 2008
11. Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... RESEARCH TRIANGLE PARK, N.C. , April ... UTHR ) announced today that Martine Rothblatt , ... will provide an overview and update on the company,s ... Health Care Conference. The presentation will take ... Eastern Time, and can be accessed via a live ...
(Date:4/27/2016)... ... April 27, 2016 , ... Global Stem Cells Group CEO Benito ... the founder of GSCG affiliate Kimera Labs in Miami. , In 2004, Ross received ... cell transplantation for hematologic disorders and the suppression of graft vs. host disease (GVHD) ...
(Date:4/26/2016)... ... April 26, 2016 , ... BaseHealth , ... joined the company as Chief Business Officer. Arianpour, a genomics pioneer and visionary ... market, was most recently Chief Commercial Officer of Pathway Genomics. He has held ...
(Date:4/26/2016)... ... April 26, 2016 , ... BioFactura, Inc ., a biopharmaceutical research and ... Healthy investor interest drove significant oversubscription of the original $1.5M target. The ... to the advanced preclinical stages. , Chief Executive Officer and President, Darryl Sampey ...
Breaking Biology Technology:
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
(Date:3/17/2016)... 2016 ABI Research, the leader in ... biometrics market will reach more than $30 billion ... 2015. Consumer electronics, particularly smartphones, continue to boost ... to reach two billion shipments by 2021 at ... , Research Analyst at ABI Research. "Surveillance is ...
Breaking Biology News(10 mins):